TABLE 2

Regression Analysis of Clinical Parameters and Their Respective Risk for PSMA PET/CT Detection (n = 55)

Variable	n	Odds ratio for PET-positive	P	Odds ratio for PET M1	P
Age ≥ 65	40 of 55 (73)	1.3 (0.3–4.9)	0.75	0.9 (0.3–3.1)	0.91
Gleason score ≥ 8	28 of 47 (60)	1.3 (0.2–5.1)	0.70	1.2 (0.4–3.9)	0.77
PSA ≥ 1.5 ng/mL	28 of 55 (51)	3.0 (0.8–11.3)	0.11	2.0 (0.7–5.8)	0.22
PSA doubling time ≤ 6 mo	27 of 44 (61)	0.8 (0.2–3.5)	0.82	1.3 (0.4–4.2)	0.70
Locoregional disease pT3/pT4^*	20 of 31 (65)	1.5 (0.2–9.4)	0.60	1.2 (0.3–5.2)	0.81
Locoregional disease pN1^†	12 of 30 (40)	1.4 (0.2–9.4)	0.71	0.6 (0.1–2.5)	0.46
Primary radiation therapy	11 of 55 (20)	0.5 (0.1–2.1)	0.36	0.1 (0.0–0.7)	0.02^*

↵* Analyzed for all patients after prostatectomy with known pT stage.
↵† Analyzed for all patients after lymphadenectomy with known pN stage.
Data in parentheses are percentage or 95% confidence interval.